Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 181

Sort by

Sort Order Select

Journal Articles

Updated Results from a Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML

Blood (2024) 144 (Supplement 1): 1007.

https://doi.org/10.1182/blood-2024-208684

Published: 2024

Journal Articles

CHOP Is Insufficient for Newly-Diagnosed Subcutaneous Panniculitis-like T-Cell Lymphoma Patients: A Retrospective Study of 32 Patients in China

Chao Chen, Jingjing Yin, Wei Wang, Danqing Zhao, Chong Wei, Cong-Wei Jia, Wei Zhang, Jian Li, Daobin Zhou, Yan Zhang

Blood (2024) 144 (Supplement 1): 6395.

https://doi.org/10.1182/blood-2024-202966

Published: 2024

Journal Articles

Clonal Architecture Analysis of TET2 Mutations in Myelodysplastic Neoplasms

Yudi Zhang, Wei Wang, Lingxu Jiang, Xiaozhen Liu, Huchu Yu, Hongyan Tong

Blood (2024) 144 (Supplement 1): 6749.

https://doi.org/10.1182/blood-2024-210214

Published: 2024

Journal Articles

A Retrospective Analysis of Efficacy and Safety of Orelabrutinib Maintenance in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Zhiming Li, Jun Fang, Huilai Zhang, Wei Wang, Hui Li, Hui Zhou, Liqun Zou, Hong Cen, Wen Shujuan, Wuping Li, Peng Sun, Panpan LIU, Hang Yang, Yu Wang

Blood (2024) 144 (Supplement 1): 6542.

https://doi.org/10.1182/blood-2024-204292

Published: 2024

Journal Articles

Impact of Flow Cytometry-Based Measurable Residual Disease Clearance Kinetics in Patients with Acute Myeloid Leukemia Undergoing Intensive Chemotherapy

Wei-Ying Jen, Koji Sasaki, Farhad Ravandi, Tapan M. Kadia, Sa A. Wang, Wei Wang, Sanam Loghavi, Naval Daver, Courtney D. DiNardo, Ghayas C. Issa, Hussein A. Abbas, Cedric Nasnas, Alex Bataller, Samuel Urrutia, Sherry Pierce, Hagop M. Kantarjian, Nicholas J. Short

Blood (2024) 144 (Supplement 1): 1572.

https://doi.org/10.1182/blood-2024-212036

Published: 2024

Journal Articles

Single-Cell Sequencing Reveals Differential Erythroid Lineage Differentiation in Patients with PNH

Junshu Wu, Hui Liu, Liyan Li, Wei Wang, Zhaoyun Liu, Rong Fu

Blood (2024) 144 (Supplement 1): 1078.

https://doi.org/10.1182/blood-2024-208178

Published: 2024

Journal Articles

TP53 Mutations Distinguish a Class of Highly Homogenous Myeloid Neoplasms within MDS and AML in the Context of Complex Karyotype

Hongyan Tong, Ye Yang, Lingxu Jiang, Xinping Zhou, Liya Ma, Gaixiang Xu, Yudi Zhang, Wei Wang, Xiaozhen Liu, Huchu Yu

Blood (2024) 144 (Supplement 1): 6712.

https://doi.org/10.1182/blood-2024-207477

Published: 2024

Journal Articles

Rituximab Reduces Immunogenicity and Increases Complete Remissions without Minimal Residual Disease in Relapsed/Refractory Hairy Cell Leukemia Patients Receiving Moxetumomab Pasudotox

Robert J. Kreitman, Constance M. Yuan, Hao-Wei Wang, Hong Zhou, Mark Raffeld, Liqiang Xi, Evgeny Arons, Julie Feurtado, Lacey James, Raul C. Braylan, Katherine R. Calvo, Irina Maric, Ira Pastan

Blood (2024) 144 (Supplement 1): 6791.

https://doi.org/10.1182/blood-2024-199569

Published: 2024

Journal Articles

RNA-Lnp-Mediated CAR-T Cell Manufacturing: A Paradigm Shift in Precision Immunotherapy

Xiulian Sun, Sheng Zhao, Wei Wang

Blood (2024) 144 (Supplement 1): 2097.

https://doi.org/10.1182/blood-2024-204121

Published: 2024

Journal Articles

A Phase I Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with High Risk or Refractory/Relapsed Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation

Blood (2024) 144 (Supplement 1): 1047.

https://doi.org/10.1182/blood-2024-211343

Published: 2024

Journal Articles

Initial Experience with CD19/CD22 BiCistronic CAR T-Cells in Children and Young Adults with Recurrent or Refractory B-Cell Malignancies

Brynn B. Duncan, Sara K. Silbert, Alexander W. Rankin, Bonnie Yates, Lauren Little, Toni Foley, Hao-Wei Wang, Constance M. Yuan, Dana I. Delgado Colon, Yanyu Wang, Jon Inglefield, John A Ligon, Hannah W. Song, Steven L. Highfill, Haneen Shalabi, David F. Stroncek, Naomi Taylor, Nirali N. Shah

Blood (2024) 144 (Supplement 1): 680.

https://doi.org/10.1182/blood-2024-198259

Published: 2024

Journal Articles

Optimized Recombinant Human Thrombopoietin(rhTPO) Regimen Versus Eltrombopag for Pre-Treated Patients with Primary Immune Thrombocytopenia: Interim Results from a Prospective, Multicenter, Randomized Trial (TE-ITP study)

Yunfei Chen, Ting Sun, Da Gao, Wei Wang, ZePing Zhou, Guangxun Gao, Yi Wang, Hu Zhou, Yanping Song, Yinghui Lai, Zhenyu Yan, Jinsong Yan, Jie Bai, Lei Zhang

Blood (2024) 144 (Supplement 1): 3937.

https://doi.org/10.1182/blood-2024-202716

Published: 2024

Journal Articles

Long-Term Remission and Survival in Patients with Rituximab-Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma after Treatment with U16 (CD20 CAR-T cells)

Qian Cheng, JingWen Tan, Rui Liu, Liqing Kang, Hongjia Zhu, Yi Zhang, Erhua Wang, Ying Li, Jian Zhang, Han Xiao, Rong He, Xiaoyan Lou, Nan Xu, Wei Wang, Zhou Yu, Minghao Li, Hongfei Gu, Lei Yu, Xin Li

Blood (2024) 144 (Supplement 1): 3447.

https://doi.org/10.1182/blood-2024-200516

Published: 2024

Journal Articles

The Efficacy and Safety of Selinexor in Combination with Ruxolitinib in Ruxolitinib-Treated Myelofibrosis Patients: The Interim Analysis of a Prospective, Open-Label, Multicenter, Parallel-Cohort, Phase 2 Study

Minghui Duan, Lan Ma, Qiuling Wu, Hong Liang, Wei Wang, Lijun Mu, Hai Lin, Hebing Zhou, Hong-xia Shi, Jinghua Wang, Hongmei Jing

Blood (2024) 144 (Supplement 1): 1002.

https://doi.org/10.1182/blood-2024-201204

Published: 2024

Journal Articles

A Randomized Phase 2 Trial of 2nd-Line Cladribine with Concurrent or Delayed Rituximab in Patients with Classic Hairy Cell Leukemia

Robert J. Kreitman, Hao-Wei Wang, Dana I. Delgado Colon, Hong Zhou, Evgeny Arons, Mark Raffeld, Liqiang Xi, Julie Feurtado, Lacey James, Raul C. Braylan, Katherine R. Calvo, Irina Maric, Constance M. Yuan

Blood (2024) 144 (Supplement 1): 863.

https://doi.org/10.1182/blood-2024-202793

Published: 2024

Journal Articles

Multicenter Real-World Use of Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma(DLBCL) of Frontline and Relapse/Refractory Settings in China

Zhangyuting He, Huiying Zhu, Chong Wei, Danqing Zhao, Wei Wang, Jian Li, Wei Zhang, Daobin Zhou, Yan Zhang

Blood (2024) 144 (Supplement 1): 6504.

https://doi.org/10.1182/blood-2024-203008

Published: 2024

Journal Articles

High Risk Cytogenetic Abnormalities Are Poor Prognostic Factors for Newly Diagnosed Multiple Myeloma Patients Received Autologous Hematopoietic Cell Transplantation

Blood (2024) 144 (Supplement 1): 6925.

https://doi.org/10.1182/blood-2024-205155

Published: 2024

Journal Articles

Efficacy and Safety of Carfilzomib-Based Regiments for the Treatment of Relapsed or Refractory Multiple Myeloma: Single-Center Real-Word Data

Weiwei Zhao, Juan Liu, Liyan Chen, Lianjie Wang, Yanming Xue, Yaoyao Tian, Yao Liu, Xiushuai Dong, Yuying Chang, Xi Chen, Liqian Yu, Xiaomin Zhang, Yinglan Jin, Yan Song, Biqing Han, Dandan Yao, Wei Wang

Blood (2024) 144 (Supplement 1): 7024.

https://doi.org/10.1182/blood-2024-204383

Published: 2024

Journal Articles

Trends and Attributable Risk Factors of the Global Burden of Lymphoid Malignancies over the Past Fifteen Years

Hongyan Tong, Wei Lang, Wei Wang, Yingwan Luo, Wenli Yang, Li Ye, Wenbin Yang, Hua Huang, Xinghua Zhen

Blood (2024) 144 (Supplement 1): 7579.

https://doi.org/10.1182/blood-2024-206675

Published: 2024

Journal Articles

Carfilzomib, Pomalidomide, Dexamethasone with and without Daratumumab in Relapsed/Refractory Multiple Myeloma: A Multi-Center, Prospective Real World Study in China

Fujing Zhang, Wei Wang, Hua Wang, Wei Wang, Aijun Liu, Weiwei Tian, Xiaoqi Qin, Zhongjun Xia, Junling Zhuang

Blood (2024) 144 (Supplement 1): 6985.

https://doi.org/10.1182/blood-2024-209342

Published: 2024

NARROW

Updated Results from a Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML

CHOP Is Insufficient for Newly-Diagnosed Subcutaneous Panniculitis-like T-Cell Lymphoma Patients: A Retrospective Study of 32 Patients in China

Clonal Architecture Analysis of TET2 Mutations in Myelodysplastic Neoplasms

A Retrospective Analysis of Efficacy and Safety of Orelabrutinib Maintenance in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Impact of Flow Cytometry-Based Measurable Residual Disease Clearance Kinetics in Patients with Acute Myeloid Leukemia Undergoing Intensive Chemotherapy

Single-Cell Sequencing Reveals Differential Erythroid Lineage Differentiation in Patients with PNH

TP53 Mutations Distinguish a Class of Highly Homogenous Myeloid Neoplasms within MDS and AML in the Context of Complex Karyotype

Rituximab Reduces Immunogenicity and Increases Complete Remissions without Minimal Residual Disease in Relapsed/Refractory Hairy Cell Leukemia Patients Receiving Moxetumomab Pasudotox

RNA-Lnp-Mediated CAR-T Cell Manufacturing: A Paradigm Shift in Precision Immunotherapy

A Phase I Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with High Risk or Refractory/Relapsed Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation

Initial Experience with CD19/CD22 BiCistronic CAR T-Cells in Children and Young Adults with Recurrent or Refractory B-Cell Malignancies

Optimized Recombinant Human Thrombopoietin(rhTPO) Regimen Versus Eltrombopag for Pre-Treated Patients with Primary Immune Thrombocytopenia: Interim Results from a Prospective, Multicenter, Randomized Trial (TE-ITP study)

Long-Term Remission and Survival in Patients with Rituximab-Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma after Treatment with U16 (CD20 CAR-T cells)

The Efficacy and Safety of Selinexor in Combination with Ruxolitinib in Ruxolitinib-Treated Myelofibrosis Patients: The Interim Analysis of a Prospective, Open-Label, Multicenter, Parallel-Cohort, Phase 2 Study

A Randomized Phase 2 Trial of 2nd-Line Cladribine with Concurrent or Delayed Rituximab in Patients with Classic Hairy Cell Leukemia

Multicenter Real-World Use of Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma(DLBCL) of Frontline and Relapse/Refractory Settings in China

High Risk Cytogenetic Abnormalities Are Poor Prognostic Factors for Newly Diagnosed Multiple Myeloma Patients Received Autologous Hematopoietic Cell Transplantation

Efficacy and Safety of Carfilzomib-Based Regiments for the Treatment of Relapsed or Refractory Multiple Myeloma: Single-Center Real-Word Data

Trends and Attributable Risk Factors of the Global Burden of Lymphoid Malignancies over the Past Fifteen Years

Carfilzomib, Pomalidomide, Dexamethasone with and without Daratumumab in Relapsed/Refractory Multiple Myeloma: A Multi-Center, Prospective Real World Study in China

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only